

Nubeqa® (darolutamide) - New drug approval

- On July 30, 2019, <u>Bayer announced</u> the FDA approval of <u>Nubeqa (darolutamide)</u>, for the treatment
 of patients with non-metastatic castration-resistant prostate cancer (nmCRPC).
- In the U.S., over 73,000 men are estimated to be diagnosed with CRPC in 2019.
 - About 40% of these patients have prostate cancer that has not spread to other parts of the body and is also associated with a rising prostate-specific antigen level, despite a castrate testosterone level, which is known as nmCRPC.
 - About one-third of men with nmCRPC go on to develop metastases within two years.
- Nubeqa is an androgen receptor inhibitor (ARi) with a distinct chemical structure that competitively
 inhibits androgen binding, AR nuclear translocation, and AR-mediated transcription. Nubeqa
 decreased prostate cancer cell proliferation in vitro and tumor volume in mouse xenograft models of
 prostate cancer.
- The efficacy of Nubeqa was demonstrated in a placebo-controlled study (ARAMIS) conducted in 1,509 patients with nmCRPC. Patients received Nubeqa or placebo until radiographic disease progression, unacceptable toxicity or withdrawal. All patients received a gonadotropin-releasing hormone (GnRH) analog concurrently or had a bilateral orchiectomy. All patients received a gonadotropin-releasing hormone (GnRH) analog concurrently or had a bilateral orchiectomy. The major efficacy endpoint was metastasis free survival (MFS).
 - The median MFS was 40.4 months for Nubeqa-treated patients vs. 18.4 months for the placebo group (Hazard ratio 0.41; 95% CI: 0.34, 0.50; p < 0.0001).
- A warning and precaution of Nubeqa is embryo-fetal toxicity.
- The most common adverse reactions (≥ 2%) with Nubeqa use were fatigue, pain in extremity, and
 rash
- The recommended dose of Nubeqa is 600 mg (two 300 mg film-coated tablets) orally, twice daily with food.
 - Patients receiving Nubeqa should also receive a GnRH analog concurrently or should have had a bilateral orchiectomy.
- Bayer's launch plans for Nubeqa are pending. Nubeqa will be available as a 300 mg tablet.



optumrx.com

OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at **optum.com**.

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2019 Optum, Inc. All rights reserved.